Compare FKWL & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | BYSI |
|---|---|---|
| Founded | 1981 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0M | 31.4M |
| IPO Year | 1997 | 2016 |
| Metric | FKWL | BYSI |
|---|---|---|
| Price | $2.43 | $0.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 10.1K | ★ 80.2K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 94.12 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $46,086,901.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.65 | N/A |
| 52 Week Low | $2.21 | $0.57 |
| 52 Week High | $5.48 | $2.44 |
| Indicator | FKWL | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 47.65 |
| Support Level | $2.21 | $0.67 |
| Resistance Level | $2.48 | $0.80 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 40.00 | 69.43 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.